Benzinga | Dec 8, 2020 07:51AM EST

Citigroup Upgrades Lexicon Pharmaceuticals to Buy, Raises Price Target to $6

Citigroup analyst Yigal Nochomovitz upgrades Lexicon Pharmaceuticals (NASDAQ:LXRX) from Neutral to Buy and raises the price target from $2.1 to $6.